CMS's GUIDE Model is an eight-year voluntary Medicare payment program that pays participating dementia-care organizations to coordinate care for people with dementia and support their unpaid caregivers, and 2026 brings changed quality measures that determine part of that payment. Families don't pay into GUIDE or get billed for it directly — CMS pays participants, and the quality scores shape how much those participants receive. GUIDE stands for Guiding an Improved Dementia Experience, an Innovation Center model that launched July 1, 2024, and now runs in all states, U.S.
territories, and D.C. for Medicare fee-for-service beneficiaries with a dementia diagnosis and their caregivers, according to CMS's GUIDE Model page. For 2026, CMS swapped out how it measures medication safety and caregiver strain, changes that affect the care a family may notice without ever seeing the underlying paperwork.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from CMS — Use this primary source to verify the official guidance.
- Read the original report from CMS — Use this primary source to review the complete report.
Table of Contents
- What changed in the 2026 quality measures
- How these measures affect what a participant gets paid
- What GUIDE actually covers for caregivers right now
- How to find out if a family's own provider participates
- What families should watch for in 2026
- Frequently Asked Questions
What changed in the 2026 quality measures
CMS's GUIDE Performance Measurement Manual, Version 3.0, dated May 18, 2026, replaced the medication-safety measure for performance year 2026. The prior measure, HRRx, relied on participants pulling data from patient charts and self-reporting it. The new measure, Use of High-Risk Medications in Older Adults (DAE), is calculated from Medicare claims instead, according to CMS's GUIDE Performance Measurement Manual v3.0. That shift matters because a claims-based measure draws on what Medicare actually paid for, not what a provider chooses to document.
NCQA, which maintains the technical specifications CMS uses, lists two measures feeding into participants' payment adjustments for the 2026 model year: the DAE medication measure and Potentially Harmful Drug-Disease Interactions in Older Adults (DDE), according to NCQA's GUIDE measure specification hub. Both track whether a beneficiary was prescribed medications considered risky given their age or their existing conditions. The same manual also renamed and risk-adjusted the quality-of-life measure, now called Quality of Life for Patients Living with Dementia (QoL-PLWD), and replaced the former Caregiver Burden measure with new Caregiver-Reported Impact in Dementia (CID) specifications, effective for performance year 2026, per CMS's manual. Risk-adjusting the quality-of-life score means a participant's result is compared against patients with similar baseline health, not judged on a flat scale — a change meant to keep organizations from being penalized simply for serving sicker or more advanced dementia populations.
How these measures affect what a participant gets paid
CMS does not pay these funds to beneficiaries or families. It pays participating organizations a monthly per-beneficiary Dementia Care Management Payment, and that payment is adjusted up or down based on a performance-based adjustment tied to the quality measures, plus a separate health equity adjustment, under the GUIDE Payment Methodology Paper v3.0, effective June 1, 2026.
In practical terms, an organization that documents poor medication safety scores or weak caregiver-impact results can see its monthly payment reduced, while one that performs well can see it increased. For a family, the quality measures are an indirect signal: they reflect how closely a specific GUIDE participant is managing medication risk and caregiver strain across its whole patient population, not a score tied to any one person's case.
What GUIDE actually covers for caregivers right now
Every GUIDE participant is required to provide caregivers with a 24/7 support line for urgent questions, evidence-based caregiver training, and a trained care navigator, built into the model's required care-delivery components rather than billed as separate patient services, according to CMS's GUIDE Model Overview Fact Sheet. A care navigator is the point of contact who helps coordinate a beneficiary's care across providers and connects the caregiver with available services.
GUIDE also includes respite care, which pays for temporary relief care so an unpaid caregiver can rest, travel, or attend to other responsibilities. For performance year 2025, CMS capped respite-care reimbursement at $2,563 per eligible beneficiary annually, up from $2,500 at the 2024 launch, covering in-home care, adult day programs, and facility-based respite for caregivers of beneficiaries with moderate-to-severe dementia, per the GUIDE Payment Methodology Paper. The 2026 respite figure is set in the same methodology paper's v3.0 update.
- A 24/7 caregiver support line for urgent questions
- Evidence-based caregiver training
- A dedicated, trained care navigator
- Respite care reimbursement, capped annually per beneficiary
How to find out if a family's own provider participates
CMS's most recent public participant listing counted 330 GUIDE organizations overall: 89 from the original 2024 cohort and 241 from a second cohort that began performance July 1, 2025, according to CMS's GUIDE Model FAQs. CMS has not published a 2026 count of how many beneficiaries are actually aligned to those participants, so the organization count alone doesn't say how many people are enrolled.
A family wondering whether their loved one's dementia-care provider is a GUIDE participant should ask the provider directly whether they're enrolled in CMS's GUIDE Model, since CMS's public materials list participating organizations without a simple name-lookup tool built for families. Because GUIDE is a Medicare fee-for-service model, a beneficiary enrolled in a Medicare Advantage plan should also confirm with their provider whether GUIDE applies to their specific coverage.
What families should watch for in 2026
The move to a claims-based medication-safety measure means participants no longer self-report this data, which reduces the chance that incomplete chart documentation understates a problem. Families working with a GUIDE participant can reasonably expect more consistent scrutiny of high-risk prescriptions and drug-disease interactions for 2026, since both measures now feed directly into the organization's payment adjustment under CMS's manual.
The renamed Caregiver-Reported Impact in Dementia (CID) measure also means caregiver feedback carries more defined weight in 2026 than it did under the earlier Caregiver Burden specification. A caregiver who is asked to complete a survey or questionnaire by a GUIDE participant is contributing data that affects that organization's payment adjustment, so an accurate, candid response reflects directly in the measure CMS uses.
Frequently Asked Questions
Does a family pay anything to participate in GUIDE through their provider?
No. CMS pays participating organizations directly; GUIDE is not a separate charge to beneficiaries or their families.
Is GUIDE available everywhere?
Yes. It covers Medicare fee-for-service beneficiaries with dementia in all states, U.S. territories, and D.C., according to CMS's GUIDE Model page.
What is the respite care benefit worth?
For performance year 2025, CMS capped it at $2,563 per eligible beneficiary annually for caregivers of beneficiaries with moderate-to-severe dementia, per the GUIDE Payment Methodology Paper.
How many organizations currently participate in GUIDE?
CMS's most recent count was 330 organizations: 89 from the 2024 cohort and 241 from the second cohort starting July 2025, per CMS's GUIDE Model FAQs.
You Might Also Like
- CMS GUIDE Dementia Care Payment Changes in 2026: What Comes Next and What Medicare Families Should Watch
- Food Access and Brain Health Research Priorities in 2026: What the Findings Mean for Rural Dementia Families
- CMS GUIDE Caregiver Education and Training in 2026: What Rural Dementia Families Can Verify Locally
